Park Medi World to Enter Uttarakhand with Rs 177-Crore Acquisition of Rudrapur’s Medicity Hospital

IMT News Desk
IMT News Desk
· 2 min read
Park Medi World to acquire Rudrapur’s Medicity Hospital for Rs 177 crore, marking its entry into Uttarakhand with a 330-bed multi-speciality facility.

Park Medi World Limited has announced an all-cash transaction to acquire 100 per cent shareholding in The Medicity Hospital, Rudrapur, for about Rs 177 crore, marking the hospital chain’s entry into Uttarakhand and expansion into its sixth state. The deal, routed through the acquisition of V3 Healthcare Private Limited, which operates The Medicity Hospital, will be executed in two tranches, with 80 per cent stake to be acquired by August 31, 2026 and the remaining 20 per cent by April 30, 2030.

The Medicity Hospital in Rudrapur is a 330-bed, NABH-accredited multi-super speciality facility and is positioned among the largest hospitals in the Kumaon region. Spread across about 7,000 square metres with roughly 1.64 lakh square feet of built-up area, the hospital offers more than 20 specialities and is equipped with modern medical infrastructure catering to a wide range of clinical services. According to recent financial disclosures, the hospital reported a turnover of around Rs 55.74 crore in FY 2025–26 (unaudited), reflecting steady revenue growth over the past three years.

Park Medi World, which has been pursuing a brownfield-led expansion strategy across North India, said the acquisition is aligned with its focus on high-potential, underserved healthcare markets and on driving operational synergies and economies of scale. The company expects the transaction to strengthen its regional network, improve bed utilisation and support its financial performance over the medium to long term as services are expanded and operations integrated. In a statement, the management described the Rudrapur acquisition as a key milestone in building a world-class, pan-North India healthcare network and indicated plans to further enhance clinical programmes at the newly acquired facility.

Read Next

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care
News
July 17, 2026

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care

Menthra, an AI-powered emotional wellbeing platform, today announced the launch of Menthra Care in India, expanding its platform to connect users with verified therapists, coaches, licensed clinical professionals and care organisations when they need support beyond an AI companion. The launch follows Menthra’s India debut in June, which saw tens of thousands of users join […]
Article by: IMT News Desk
IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care
News
July 17, 2026

IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care

Against a backdrop of geopolitical uncertainty, supply chain disruptions and rapid advances in artificial intelligence (AI) and precision medicine, FutureHealth.Now provided a platform for industry leaders to explore how innovation, technology and new models of care can help tackle rising healthcare costs, workforce pressures and growing demand for services across the region. At his opening […]
Article by: IMT News Desk
Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill
News
July 16, 2026

Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill

Novo Nordisk has secured European Commission approval for its once-daily Wegovy pill, giving the Danish drugmaker a major boost in the fast-growing obesity-treatment market. The approval makes it the first oral GLP-1 weight-loss treatment cleared in the European Union for adults with obesity or overweight who also have at least one weight-related health condition. The […]
Article by: IMT News Desk
Sun Pharma Wins South Africa Approval to Launch Generic Ozempic
News
July 16, 2026

Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

India’s Sun Pharmaceutical Industries has received approval from South Africa’s health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, expanding its presence in the fast-growing GLP-1 market. The South African Health Products Regulatory Authority’s clearance allows Sun Pharma to market the injectable treatment for […]
Article by: IMT News Desk